Copper suppression as cancer therapy: the rationale for copper chelating agents in

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

19 citing papers in PubMed, 33 citations in OpenAlex.

1. Multifaceted Role of Copper Homeostasis in Gut Health: From Molecular Mechanisms to Therapeutic Interventions.Cells · 2026
   Review
2. The molecular mechanism and therapeutic landscape of copper and cuproptosis in cancer.Signal transduction and targeted therapy · 2025
   Review
3. Cuproplasia and cuproptosis in hepatocellular carcinoma: mechanisms, relationship and potential role in tumor microenvironment and treatment.Cancer cell international · 2025
   Review
4. Metal Ion Signaling in Biomedicine.Chemical reviews · 2025
   Review
5. Copper Dyshomeostasis and Diabetic Complications: Chelation Strategies for Management.Mini reviews in medicinal chemistry · 2025
   Review
6. Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy.Journal of experimental & clinical cancer research : CR · 2024
   Article
7. Evolving approaches in glioma treatment: harnessing the potential of copper metabolism modulation.RSC advances · 2023
   Review
8. Copper chelation suppresses epithelial-mesenchymal transition by inhibition of canonical and non-canonical TGF-β signaling pathways in cancer.Cell & bioscience · 2023
   Article
9. The huge potential of targeting copper status in the treatment of colorectal cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
   Review
10. AMPK phosphorylates and stabilises copper transporter 1 to synergise metformin and copper chelator for breast cancer therapy.British journal of cancer · 2023
    Article
11. Influence of Silver Nanoparticles on the Growth of Ascitic and Solid Ehrlich Adenocarcinoma: Focus on Copper Metabolism.Pharmaceutics · 2023
    Article
12. Relationship between copper and immunity: The potential role of copper in tumor immunity.Frontiers in oncology · 2022
    Review
13. Copper depletion modulates mitochondrial oxidative phosphorylation to impair triple negative breast cancer metastasis.Nature communications · 2021
    Article
14. Modulation of Intracellular Copper Levels as the Mechanism of Action of Anticancer Copper Complexes: Clinical Relevance.Biomedicines · 2021
    Review
15. The Crossroads between Host Copper Metabolism and Influenza Infection.International journal of molecular sciences · 2021
    Review
16. Disulfiram as a Therapeutic Agent for Metastatic Malignant Melanoma-Old Myth or New Logos?Cancers · 2020
    Review
17. Current Biomedical Use of Copper Chelation Therapy.International journal of molecular sciences · 2020
    Review
18. Effects of Copper Chelation on BRAFCancers · 2019
    Article
19. Iron and Copper Intracellular Chelation as an Anticancer Drug Strategy.Inorganics · 2018
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors at 4 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as